Who makes PROT-CL-NP101-015.01?

PROT-CL-NP101-015.01 is developed by NuPathe Inc..

What development phase is PROT-CL-NP101-015.01 in?

PROT-CL-NP101-015.01 is in Phase 1.

Last reviewed 2026-05-15 · How we verify

PROT-CL-NP101-015.01

NuPathe Inc. · Phase 1 active Small molecule

At a glance

Generic name	PROT-CL-NP101-015.01
Also known as	Zecuity®, Sumatriptan
Sponsor	NuPathe Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety, Pharmacokinetic, and Tolerability Study of Zecuity® in Adolescent Subjects With a History of Acute Migraine (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

PROT-CL-NP101-015.01 CI brief — competitive landscape report
PROT-CL-NP101-015.01 updates RSS · CI watch RSS
NuPathe Inc. portfolio CI